Metabotropic Glutamate Receptors as Targets for Novel Antipsychotic Treatments

Author(s): L. J. Gray, A. J. Hannan, X. Zhang

Journal Name: Current Pharmaceutical Biotechnology

Volume 13 , Issue 8 , 2012

Become EABM
Become Reviewer
Call for Editor


In recent years metabotropic glutamate receptors have emerged as key targets for the design of new antipsychotic medications for schizophrenia, in particular mGluR5 and mGluR2/3. These receptors exhibit diverse interactions with other neurotransmitter receptors and critical elements of intracellular signalling cascades known to be important to the pharmacotherapy of schizophrenia. In addition, mGluR5 and mGluR2/3 are intimately involved in behavioural domains related to the symptoms of this disorder. Both animal and clinical studies using novel drugs targeting these receptors have provided encouraging results. The number of patents registered for drugs targeting metabotropic glutamate receptors has grown dramatically, and positive allosteric modulators for both receptors show particular promise.

Keywords: Schizophrenia, Antipsychotic, Metabotropic Glutamate receptors, mGluR5; mGluR2, mGluR3, metabotropic glutamate receptors, key targets, "antipsychotic medications", "schizophrenia", neurotransmitter receptors, critical elements, signalling cascades, pharmacotherapy

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2012
Published on: 27 May, 2012
Page: [1522 - 1534]
Pages: 13
DOI: 10.2174/138920112800784817
Price: $65

Article Metrics

PDF: 12